As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy

Just days after UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO, the company reported updated data on Jan. 8 showing that

Read the full 240 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE